PMID- 35125314
OWN - NLM
STAT- MEDLINE
DCOM- 20220301
LR  - 20220301
IS  - 1166-7087 (Print)
IS  - 1166-7087 (Linking)
VI  - 32
IP  - 3
DP  - 2022 Mar
TI  - [Guidelines from the cancer (CC-AFU) and infection disease (CI-AFU) committees of 
      the French Association of Urology for the management of adverse events and 
      complications of BCG].
PG  - 165-176
LID - S1166-7087(22)00001-X [pii]
LID - 10.1016/j.purol.2022.01.001 [doi]
AB  - INTRODUCTION: Intravesical instillations of BCG are recommended for the treatment 
      of high-risk non-muscle-invasive bladder cancer. However, their prolonged use 
      remains limited by the associated potentially serious adverse effects or 
      complications. The purpose of this article was to provide updated recommendations 
      for the diagnosis and management of adverse events (AEs) or complications of 
      intravesical BCG instillations. MATERIALS AND METHODS: Review of the literature 
      in Medline (http://www.ncbi.nlm.nih.gov) and Embase (http://www.embase.com) using 
      the following MeSH keywords or a combination of these keywords: "bladder," "BCG," 
      "complication," "toxicity," "adverse events," "prevention," and "treatment". 
      RESULTS: AEs or complications of BCG included genitourinary and systemic 
      symptoms. The most common complications (cystitis, moderate fever) should be 
      treated symptomatically and may require adjustment to allow patients to have the 
      most complete BCG treatment possible. Serious complications are rare but must be 
      identified promptly because of the life-threatening nature of the disease. Their 
      management is based on the combination of anti-tuberculosis treatments, 
      anti-inflammatory drugs and the definitive discontinuation of BCG. CONCLUSION: 
      The management of BCG AEs requires early identification, rational and effective 
      treatment if necessary, and discussion of the continuation of treatment for each 
      situation.
CI  - Copyright (c) 2022 Elsevier Masson SAS. All rights reserved.
FAU - Audenet, F
AU  - Audenet F
AD  - Service d'urologie, hopital europeen Georges-Pompidou, universite de Paris, 
      Paris, France.
FAU - Sotto, A
AU  - Sotto A
AD  - Service des maladies infectieuses et tropicales, CHU de Nimes, Nimes, France.
FAU - Roumiguie, M
AU  - Roumiguie M
AD  - Service d'urologie, CHU institut universitaire du cancer de Toulouse, Toulouse, 
      France.
FAU - Allory, Y
AU  - Allory Y
AD  - Service d'anatomopathologie, institut Curie, universite de Paris Saclay, 
      Saint-Cloud, France.
FAU - Andrejak, C
AU  - Andrejak C
AD  - Service de pneumologie, CHU d'Amiens-Picardie, Amiens, France.
FAU - Leon, P
AU  - Leon P
AD  - Service d'urologie, clinique Pasteur, Royan, France.
FAU - Loriot, Y
AU  - Loriot Y
AD  - Service d'oncologie medicale, institut Gustave-Roussy, Inserm U981, Villejuif, 
      France.
FAU - Masson-Lecomte, A
AU  - Masson-Lecomte A
AD  - Service d'urologie, hopital Saint-Louis, universite de Paris, Paris, France.
FAU - Pradere, B
AU  - Pradere B
AD  - Department of urology, comprehensive cancer center, medical university of Vienna, 
      Vienna, L'Autriche.
FAU - Seisen, T
AU  - Seisen T
AD  - Service d'urologie, hopital Pitie-Salpetriere, universite Paris Sorbonne, Paris, 
      France.
FAU - Traxer, O
AU  - Traxer O
AD  - Service d'urologie, hopital Bichat, universite de Paris, Paris, France.
FAU - Xylinas, E
AU  - Xylinas E
AD  - Service d'urologie, hopital Tenon, universite Paris Sorbonne, Paris, France.
FAU - Bruyere, F
AU  - Bruyere F
AD  - Service d'urologie, CHRU de Tours, Tours, France.
FAU - Roupret, M
AU  - Roupret M
AD  - Service d'urologie, hopital Pitie-Salpetriere, universite Paris Sorbonne, Paris, 
      France.
FAU - Saint, F
AU  - Saint F
AD  - Service d'urologie, CHU d'Amiens-Picardie, Amiens, France.
FAU - Neuzillet, Y
AU  - Neuzillet Y
AD  - Service d'urologie, hopital Foch, universite de Paris Saclay, 40, rue Worth, 
      Suresnes, France. Electronic address: y.neuzillet@hopital-foch.com.
LA  - fre
PT  - Journal Article
TT  - Recommandations des Comites de cancerologie (CC-AFU) et d'infectiologie (CI-AFU) 
      de l'Association francaise d'urologie pour la prise en charge effets indesirables 
      et complications du BCG.
DEP - 20220203
PL  - France
TA  - Prog Urol
JT  - Progres en urologie : journal de l'Association francaise d'urologie et de la 
      Societe francaise d'urologie
JID - 9307844
RN  - 0 (Adjuvants, Immunologic)
RN  - 0 (BCG Vaccine)
SB  - IM
MH  - Adjuvants, Immunologic/adverse effects
MH  - Administration, Intravesical
MH  - BCG Vaccine/adverse effects
MH  - Humans
MH  - *Urinary Bladder Neoplasms/drug therapy
MH  - *Urology
OTO - NOTNLM
OT  - Antibiotherapie
OT  - Antibiotic therapy
OT  - BCG therapy
OT  - BCG therapie
OT  - Bladder
OT  - Carcinome urothelial
OT  - Complications
OT  - Endovesical instillations
OT  - Instillations endovesicales
OT  - NMIBC
OT  - TVNIM
OT  - Urothelial carcinoma
OT  - Vessie
EDAT- 2022/02/08 06:00
MHDA- 2022/03/03 06:00
CRDT- 2022/02/07 05:26
PHST- 2021/12/11 00:00 [received]
PHST- 2022/01/02 00:00 [revised]
PHST- 2022/01/10 00:00 [accepted]
PHST- 2022/02/08 06:00 [pubmed]
PHST- 2022/03/03 06:00 [medline]
PHST- 2022/02/07 05:26 [entrez]
AID - S1166-7087(22)00001-X [pii]
AID - 10.1016/j.purol.2022.01.001 [doi]
PST - ppublish
SO  - Prog Urol. 2022 Mar;32(3):165-176. doi: 10.1016/j.purol.2022.01.001. Epub 2022 
      Feb 3.